Another study reported the additive effects of the COX-2 selective inhibitor Celecoxib in reducing the proliferative ability of the colon cancer cell lines HT29 and Caco-2 when combined with either the 5-LOX inhibitor MK886 or the CysLT1R antagonist LY171883. This evidence concerns the gene ALOX5 and malignant colon neoplasm.